Kymera Therapeutics COO Jeremy Chadwick to retire

Kymera Therapeutics, Inc. reported that Chief Operating Officer Jeremy Chadwick has communicated his intention to retire and submitted his resignation as COO on June 5, 2026.

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. reported that Chief Operating Officer Jeremy Chadwick has communicated his intention to retire and submitted his resignation as COO on June 5, 2026. He will remain an employee of the company as an advisor until November 2026 to support the transition.

The company states that Mr. Chadwick resigned for personal reasons and that his decision was not the result of any disagreement with Kymera’s practices or policies. The filing is framed as an orderly leadership change with continued advisory involvement over several months.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Terms

Chief Operating Officer, Emerging growth company, personal reasons, practices or policies

4 terms

Chief Operating Officer financial

"submitted his resignation as Chief Operating Officer (“COO”) on June 5, 2026"

A chief operating officer (COO) is a senior executive responsible for overseeing the day-to-day activities of a company, ensuring that all parts of the organization work smoothly and efficiently. They often act like a company's operational quarterback, translating strategic plans into practical actions. For investors, the COO's effectiveness can influence a company's performance and stability, making them an important figure in assessing the company's management strength.

Emerging growth company regulatory

"Emerging growth company    Jeremy Chadwick communicated his intention"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

personal reasons financial

"Mr. Chadwick informed the Company that he resigned as COO for personal reasons"

practices or policies financial

"not as the result of any disagreement with the Company’s practices or policies"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What executive change did Kymera Therapeutics (KYMR) disclose?

Kymera Therapeutics disclosed that Chief Operating Officer Jeremy Chadwick has decided to retire and submitted his resignation as COO on June 5, 2026. The company characterized his departure as a personal decision, not tied to disagreements over practices or policies.

Will Jeremy Chadwick remain involved with Kymera Therapeutics (KYMR)?

Yes. Although Jeremy Chadwick resigned as COO on June 5, 2026, he will remain an employee of Kymera Therapeutics as an advisor until November 2026. This advisory role is intended to help provide continuity and support during the leadership transition period.

Did Kymera Therapeutics (KYMR) report any disagreements related to the COO resignation?

No. Kymera Therapeutics reported that Jeremy Chadwick resigned as COO for personal reasons and explicitly stated his decision was not due to any disagreement with the company’s practices or policies. This language is meant to clarify that no governance dispute was disclosed.

When did Kymera Therapeutics (KYMR) COO Jeremy Chadwick resign?

Jeremy Chadwick submitted his resignation as Chief Operating Officer on June 5, 2026. The same disclosure notes that he will continue working for Kymera Therapeutics as an advisor until November 2026, supporting the company during the transition period following his departure as COO.

Who signed the Kymera Therapeutics (KYMR) report about the COO retirement?

The report describing Jeremy Chadwick’s planned retirement and resignation as COO was signed on behalf of Kymera Therapeutics by President and Chief Executive Officer Nello Mainolfi, Ph.D. His signature indicates the disclosure was authorized at the senior leadership level.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 04:05 PM Learn about SEC filing dates

MA false 0001815442 0001815442 2026-06-05 2026-06-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 5, 2026

KYMERA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39460		81-2992166
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

Kymera Therapeutics, Inc.

500 North Beacon Street, 4th Floor

Watertown, Massachusetts 02472

(Address of principal executive offices, including zip code)

(857) 285-5300

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trade Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		KYMR		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Jeremy Chadwick communicated his intention to retire and submitted his resignation as Chief Operating Officer (“COO”) on June 5, 2026. Mr. Chadwick will remain an employee of Kymera Therapeutics, Inc. (the “Company”) as an advisor until November 2026. Mr. Chadwick informed the Company that he resigned as COO for personal reasons, and not as the result of any disagreement with the Company’s practices or policies.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Kymera Therapeutics, Inc.
Date: June 8, 2026				By:		/s/ Nello Mainolfi
						Nello Mainolfi, Ph.D.
						President and Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 18.3 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.4 KB